This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT04153929 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Boehringer Ingelheim |
| Enrollment | 413 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Diabetes Mellitus, Type 2 |
| Interventions | BI 456906; Placebo; Semaglutide |
| Start | Apr 30, 2020 |
| Primary completion | Oct 8, 2021 |
| Study completion | Nov 4, 2021 |
| Results posted | Yes, in the registry |
| Registry last updated | Nov 29, 2022 |
Compounds on this site that cite this trial
What the registry says the trial is about
This study is open to adults with type 2 diabetes who take metformin but still have too high blood sugar. The purpose of the study is to find the best dose of BI 456906 that reduces blood sugar. The study also looks at whether BI 456906 helps the participants lose weight.
Participants are in the study for about 23 weeks. During this time, most participants visit the study site about 13 times. Some participants visit the study site about 20 times. At the start of the study, the participants are put into 7 groups. The participants in groups 1 to 6 get injections under the skin once or twice every week. Some participants get different doses of BI 456906 and other participants get placebo. Placebo injections look like the BI 456906 injections, but contain no medicine. Participants in group 7 get semaglutide injections every week. Semaglutide is another medicine for adults with type 2 diabetes.
During the study, the doctors regularly take blood samples from the participants and measure their body weight. The changes in blood sugar levels and body weight are compared between the groups. The doctors also check the general health of the participants.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Absolute Change in HbA1c From Baseline to 16 Weeks | At baseline and at Week 17 (16 weeks after treatment start). |
5 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
